Rabbit Antithymocyte Globulin Induction in Heart Transplant Recipients at High Risk for Rejection

REFERENCES

1. 1.↵
   1. Lund LH,
   2. Khush KK,
   3. Cherikh WS

   , et al; International Society for Heart and Lung Transplantation. The registry of the international society for heart and lung transplantation: thirty-fourth adult heart transplantation report-2017; focus theme: allograft ischemic time. J Heart Lung Transplant. 2017;36(10):1037-1046. doi: 10.1016/j.healun.2017.07.019

   OpenUrlCrossRefPubMed
2. 2.
   1. Rose EA,
   2. Gelijns AC,
   3. Moskowitz AJ

   , et al; Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH) Study Group. Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med. 2001;345(20):1435-1443. doi: 10.1056/NEJMoa012175

   OpenUrlCrossRefPubMedWeb of Science
3. 3.↵
   1. Califf RM,
   2. Adams KF,
   3. McKenna WJ,
   4. et al.

   A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: the Flolan International Randomized Survival Trial (FIRST). Am Heart J. 1997;134(1):44-54. doi: 10.1016/s0002-8703(97)70105-4

   OpenUrlCrossRefPubMedWeb of Science
4. 4.↵
   1. Kobashigawa J.

   Clinical trials in heart transplantation: the evolution of evidence in immunosuppression. J Heart Lung Transplant. 2017;36(12):1286-1290. doi: 10.1016/j.healun.2017.10.009

   OpenUrlCrossRef
5. 5.↵
   1. Carrier M,
   2. White M,
   3. Perrault LP,
   4. et al.

   A 10-year experience with intravenous thymoglobuline in induction of immunosuppression following heart transplantation. J Heart Lung Transplant. 1999;18(12):1218-1223. doi: 10.1016/s1053-2498(99)00100-x

   OpenUrlCrossRefPubMedWeb of Science
6. 6.↵
   1. Higgins R,
   2. Kirkland JK,
   3. Brown RN

   , et al; Cardiac Transplant Research Database (CTRD). To induce or not to induce: do patients at greatest risk for fatal rejection benefit from cytolytic induction therapy? J Heart Lung Transplant. 2005;24(4):392-400. doi: 10.1016/j.healun.2004.01.002

   OpenUrlCrossRefPubMedWeb of Science
7. 7.↵
   1. Emin A,
   2. Rogers CA,
   3. Thekkudan J,
   4. Bonser RS,
   5. Banner NR

   ; Steering Group, UK Cardiothoracic Transplant Audit. Antithymocyte globulin induction therapy for adult heart transplantation: a UK national study. J Heart Lung Transplant. 2011;30(7):770-777. doi: 10.1016/j.healun.2011.01.716

   OpenUrlCrossRefPubMed
8. 8.↵
   1. Zuckermann A,
   2. Ploner M,
   3. Czerny M,
   4. et al.

   Low incidence of graft arteriosclerosis after cardiac transplantation: risk factor analysis for patients with induction therapy. Transplant Proc. 2002;34(5):1869-1871. doi: 10.1016/s0041-1345(02)03103-2

   OpenUrlCrossRefPubMed
9. 9.↵
   1. Zhang R,
   2. Haverich A,
   3. Strüber M,
   4. Simon A,
   5. Bara C.

   Delayed onset of cardiac allograft vasculopathy by induction therapy using anti-thymocyte globulin. J Heart Lung Transplant. 2008;27(6):603-609. doi: 10.1016/j.healun.2008.02.016

   OpenUrlCrossRefPubMedWeb of Science
10. 10.↵
    1. Azarbal B,
    2. Cheng R,
    3. Vanichsarn C,
    4. et al.

    Induction therapy with antithymocyte globulin in patients undergoing cardiac transplantation is associated with decreased coronary plaque progression as assessed by intravascular ultrasound. Circ Heart Fail. 2016;9(1):e002252. doi: 10.1161/CIRCHEARTFAILURE.115.002252

    OpenUrlAbstract/FREE Full Text
11. 11.↵
    1. Mazimba S,
    2. Tallaj JA,
    3. George JF,
    4. Kirklin JK,
    5. Brown RN,
    6. Pamboukian SV

    . Infection and rejection risk after cardiac transplantation with induction vs. no induction: a multi-institutional study. Clin Transplant. 2014;28(9):946-952. doi: 10.1111/ctr.12395

    OpenUrlCrossRef
12. 12.↵
    1. Jarmi T,
    2. Patel N,
    3. Aslam S,
    4. et al.

    Outcomes of induction therapy with rabbit anti-thymocyte globulin in heart transplant recipients: a single center retrospective cohort study. Ann Transplant. 2018;23:422-426. doi: 10.12659/AOT.907984

    OpenUrlCrossRef
13. 13.↵
    1. Amin AA,
    2. Araj FG,
    3. Ariyamuthu VK,
    4. et al.

    Impact of induction immunosuppression on patient survival in heart transplant recipients treated with tacrolimus and mycophenolic acid in the current allocation era. Clin Transplant. 2019;33(8):e13651. doi: 10.1111/ctr.13651

    OpenUrlCrossRef
14. 14.↵
    1. Stewart S,
    2. Winters GL,
    3. Fishbein MC,
    4. et al.

    Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Lung Transplant. 2005;24(11):1710-1720. doi: 10.1016/j.healun.2005.03.019

    OpenUrlCrossRefPubMedWeb of Science
15. 15.↵
    1. Mehra MR,
    2. Crespo-Leiro MG,
    3. Dipchand A,
    4. et al.

    International society for heart and lung transplantation working formulation of a standardized nomenclature for cardiac allograft vasulopathy-2010. J Heart Lung Transplant. 2010;29(7):717-727. doi: 10.1016/j.healun.2010.05.017

    OpenUrlCrossRefPubMedWeb of Science
16. 16.↵
    1. Kobashigawa JA,
    2. Tobis JM,
    3. Starling RC,
    4. et al.

    Multicenter intravascular ultrasound validation study among heart transplant recipients: outcomes after five years. J Am Coll Cardiol. 2005;45(9):1532-1537. doi: 10.1016/j.jacc.2005.02.035

    OpenUrlFREE Full Text
17. 17.↵
    1. Michaels PJ,
    2. Espejo ML,
    3. Kobashigawa J,
    4. et al.

    Humoral rejection in cardiac transplantation: risk factors, hemodynamic consequences and relationship to transplant coronary artery disease. J Heart Lung Transplant. 2003;22(1):58-69. doi: 10.1016/s1053-2498(02)00472-2

    OpenUrlCrossRefPubMedWeb of Science
18. 18.↵
    1. Reed EF,
    2. Demetris AJ,
    3. Hammond E

    , et al; International Society for Heart and Lung Transplantation. Acute antibody-mediated rejection of cardiac transplants. J Heart Lung Transplant. 2006;25(2):153-159. doi: 10.1016/j.healun.2005.09.003

    OpenUrlCrossRefPubMedWeb of Science
19. 19.↵
    The effect and safety profile of Thymoglobulin® in primary cardiac transplant recipients. U.S. National Library of Medicine. Accessed May 5, 2020. https://clinicaltrials.gov/ct2/show/NCT03292861
20. 20.↵
    1. Hosenpud JD,
    2. Bennett LE,
    3. Keck BM,
    4. Boucek MM,
    5. Novick RJ

    . The registry of the international society for heart and lung transplantation: eighteenth official report-2001. J Heart Lung Transplant. 2001;20(8):805-815. doi: 10.1016/s1053-2498(01)00323-0

    OpenUrlCrossRefPubMedWeb of Science
21. 21.↵
    1. Kobashigawa J,
    2. Miller L,
    3. Renlund D

    , et al; Mycophenolate Mofetil Investigators. A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Transplantation. 1998;66(4):507-515. doi: 10.1097/00007890-199808270-00016

    OpenUrlCrossRefPubMedWeb of Science
22. 22.↵
    1. Kobashigawa JA,
    2. Miller LW,
    3. Russell SD

    , et al; Study Investigators. Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1-year report. Am J Transplant. 2006;6(6):1377-1386. doi: 10.1111/j.1600-6143.2006.01290.x

    OpenUrlCrossRefPubMedWeb of Science
23. 23.↵
    1. Baraldo M,
    2. Gregoraci G,
    3. Livi U

    . Steroid-free and steroid withdrawal protocols in heart transplantation: the review of the literature. Transpl Int. 2014;27(6):515-529. doi: 10.1111/tri.12309

    OpenUrlCrossRef
24. 24.↵
    1. Kilic A,
    2. Weiss ES,
    3. Allen JG,
    4. et al.

    Simple score to assess the risk of rejection after heart orthotopic heart transplantation. Circulation. 2012;125(24):3013-3021. doi: 10.1161/CIRCULATIONAHA.111.066431

    OpenUrlAbstract/FREE Full Text